Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Kalaris Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- +2 vs. Q2 2025
- Shares held
- 13.2M
- −139.4K (−1.0%) vs. Q2 2025
- Total value
- $76.4M
- +$40.8M (+114.2%) vs. Q2 2025
- New holders
- 8
- 9 more added
- Sold out
- 6
- 5 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KLRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $73.4M |
| Q1 2026 | 58 | $107.2M |
| Q4 2025 | 51 | $151.9M |
| Q3 2025 | 32 | $76.4M |
| Q2 2025 | 30 | $35.7M |
| Q1 2025 | 32 | $111.4M |
| Q4 2024 | 53 | $20.7M |
| Q3 2024 | 60 | $36.3M |
| Q2 2024 | 72 | $33.9M |
| Q1 2024 | 77 | $36.4M |
| Q4 2023 | 82 | $28.5M |
| Q3 2023 | 90 | $115.5M |
| Q2 2023 | 94 | $183.6M |
| Q1 2023 | 89 | $156.0M |
| Q4 2022 | 86 | $193.1M |
| Q3 2022 | 87 | $293.7M |
| Q2 2022 | 84 | $109.6M |
| Q1 2022 | 84 | $184.1M |
| Q4 2021 | 84 | $329.4M |
| Q3 2021 | 80 | $640.3M |
| Q2 2021 | 84 | $521.8M |
| Q1 2021 | 75 | $624.4M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Kalaris Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 11,448,081 | $66.2M | 8.64% | 00.0% | Unchanged |
| Tang Capital Management LLC | 418,241 | $2.42M | 0.09% | +57,382+15.9% | Added |
| Siren, L.L.C. | 318,264 | $1.84M | 0.07% | +35,678+12.6% | Added |
| Woodline Partners LP | 241,102 | $1.39M | 0.01% | +241,102 | New |
| Vanguard Group Inc | 203,051 | $1.17M | 0.00% | +73,212+56.4% | Added |
| Renaissance Technologies LLC | 112,751 | $651.7K | 0.00% | +16,000+16.5% | Added |
| Redmile Group, LLC | 82,955 | $479.5K | 0.05% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 64,551 | $373.1K | 0.00% | +39,075+153.4% | Added |
| BlackRock, Inc. | 40,379 | $233.4K | 0.00% | +2,223+5.8% | Added |
| Squarepoint Ops LLC | 40,173 | $232.2K | 0.00% | −18,922−32.0% | Reduced |
| Belpointe Asset Management LLC | 40,000 | $231.2K | 0.01% | +40,000 | New |
| Fortis Capital Advisors, LLC | 40,000 | $231.2K | 0.04% | +40,000 | New |
| Millennium Management LLC | 24,923 | $144.1K | 0.00% | −29,169−53.9% | Reduced |
| Morgan Stanley | 24,918 | $144.0K | 0.00% | +22,954+1,168.7% | Added |
| State Street Corp | 22,610 | $130.7K | 0.00% | +11,900+111.1% | Added |
| Bridgeway Capital Management, LLC | 22,500 | $130.1K | 0.00% | +22,500 | New |
| Goldman Sachs Group Inc | 22,465 | $129.8K | 0.00% | +22,465 | New |
| RBF Capital, LLC | 17,391 | $100.5K | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 14,115 | $81.6K | 0.00% | 00.0% | Unchanged |
| Johnson Financial Group, Inc. | 10,000 | $57.8K | 0.00% | +10,000 | New |
| FMR LLC | 7,806 | $45.1K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 5,252 | $30.4K | 0.00% | +1,136+27.6% | Added |
| Federated Hermes, Inc. | 578 | $3.34K | 0.00% | −56−8.8% | Reduced |
| Strengthening Families & Communities, LLC | 268 | $1.55K | 0.00% | +268 | New |
| Bank of America Corp | 217 | $1.25K | 0.00% | −56−20.5% | Reduced |
| BNP Paribas Arbitrage, SA | 141 | $815 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 50 | $289 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 49 | $283 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 33 | $191 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 8 | $46 | 0.00% | −2−20.0% | Reduced |
| Citigroup Inc | 1 | $6 | 0.00% | +1 | New |
| Royal Bank of Canada | 85 | $0 | 0.00% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −360,000−100.0% | Sold out |
| Gilead Sciences, Inc. | 0 | $0 | 0.00% | −317,789−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −24,234−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −20,281−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −2,629−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,153−100.0% | Sold out |